NCT05724693View on ClinicalTrials.gov

Study of Bemnifosbuvir in Subjects With Normal and Impaired Hepatic Function

PHASE1CompletedINTERVENTIONAL
Enrollment

39

Participants

Timeline

Start Date

January 30, 2023

Primary Completion Date

April 23, 2024

Study Completion Date

April 23, 2024

Conditions
Healthy VolunteerHepatic Impairment
Interventions
DRUG

Bemnifosbuvir (BEM)

Day 1: A single dose of BEM will be administered

Trial Locations (1)

32809

Atea Study Site Orlando Clinical Research Center, Orlando

Sponsors
All Listed Sponsors
lead

Atea Pharmaceuticals, Inc.

INDUSTRY

NCT05724693 - Study of Bemnifosbuvir in Subjects With Normal and Impaired Hepatic Function | Biotech Hunter | Biotech Hunter